Skinvisible Pharmaceuticals Inc. next month plans to roll out its DermSafe antimicrobial hand sanitizer in Canada.


Skinvisible, DermSafe, hand sanitizer, antimicrobial hand sanitizer, Canada, Alto Pharmaceuticals, Terry Howlett, Invisicare, ProCort, topical treatment, hemorrhoids, Women's Choice Pharmaceuticals, women's health




























































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Skinvisible's DermSafe hand sanitizer to launch in Canada

August 19th, 2011

LAS VEGAS – Skinvisible Pharmaceuticals Inc. next month plans to roll out its DermSafe antimicrobial hand sanitizer in Canada.

The Las Vegas-based company said Thursday that DermSafe will be launched by Alto Pharmaceuticals in Canada on Sept. 1, in time for the back-to-school and flu seasons.

Alto, a Toronto-based dermatology pharmaceuticals specialist, has licensed the exclusive rights to DermSafe for commercial use in Canada. Alto will market the product under the name DermSafePC.

Using Skinvisible's Invisicare delivery system, DermSafe offers advantages over alcohol-based hand sanitizers, according to Skinvisible. DermSafe is made with 4% chlorhexidine gluconate, an ingredient used in hospitals worldwide because of its effectiveness against a wide range of germs and its persistence. DermSafe hand sanitizer lotion has no alcohol and does not dry the skin like other sanitizers, instead delivering protection in a lotion formulation that defends the skin from outside irritants, the company said.

"We are pleased to see the launch of DermSafePC in Canada," stated Terry Howlett, president and chief executive officer of Skinvisible. "Alto is committed to gaining market share quickly in Canada, and we believe that the introduction of DermSafePC will help generate a very positive response from end-users as well as potential licensees worldwide."

He added, "The manufacturing of DermSafe in Canada is critical to Skinvisible as it will facilitate the quick introduction of the product in Europe and Singapore, where DermSafe is already approved for importation."

Outside Canada, DermSafe is licensed in Europe, where it recently received regulatory approval. A European launch is scheduled in the fourth quarter, Skinvisible said. The company added that it continues to negotiate additional licenses for the retail pharmacy rights in Canada and Europe, along with other parts of the world.

Last month, Skinvisible introduced its first prescription product in the United States: ProCort, a topical treatment for hemorrhoids. The product was launched by specialty pharmaceutical company Women's Choice Pharmaceuticals LLC, which holds the exclusive U.S. rights to market the product.

Targeted at the women's health market, ProCort also employs the Invisicare system, which Skinvisible said enhances the delivery of active ingredients by controlling their release and providing superior binding properties. ProCort is made of a combination of hydrocortisone acetate and pramoxine hydrochloride.

Skinvisible reported that according to the U.S. Department of Health, hemorrhoids are most common among adults over age 45 and in pregnant women, and about 75% of people will have hemorrhoids at some point in their lives.

"ProCort is Skinvisible's first prescription product launched in the United States, and we are very confident Women's Choice Pharmaceuticals will gain market share quickly, as it has with its other product launches," Howlett commented. "This is an example of how Skinvisible's Invisicare technology can meet the growing need for patent-protected options for pharmaceutical companies in dermatology and other markets."

Advertisement